We will use your email address only for sending you newsletters. Please see our Privacy Notice for details of your data protection rights.
The findings, which were published in the medical journal, The Lancet, suggest huge progress has been made in the first phases of the study. The vaccine is called AZD1222 and is being developed by AstraZeneca and scientists at the University of Oxford. It did not prompt any serious side effects and elicited antibody and T-cell immune responses, according to trial results.
Study lead author Andrew Pollard, of the University of Oxford, said: “We hope this means the immune system will remember the virus, so that our vaccine will protect people for an extended period.
“However, we need more research before we can confirm the vaccine effectively protects against SARS-CoV-2 (COVID-19) infection, and for how long any protection lasts.”
Professor Sarah Gilbert, of the University of Oxford, said: “There is still much work to be done before we can confirm if our vaccine will help manage the COVID-19 pandemic, but these early results hold promise.”
Professor Gilbert added: “As well as continuing to test our vaccine in phase-three trials, we need to learn more about the virus – for example, we still do not know how strong an immune response we need to provoke to effectively protect against Sars-Cov-2 infection.
“If our vaccine is effective, it is a promising option as these types of vaccine can be manufactured at large scale.
“A successful vaccine against Sars-Cov-2 could be used to prevent infection, disease and death in the whole population, with high-risk populations such as hospital workers and older adults prioritised to receive vaccination.”
AstraZeneca’s is among the leading vaccine candidates fighting to find a solution to the devastating pandemic which has swept the globe.
AstraZeneca has signed agreements with governments around the world to supply the vaccine should it prove effective and gain regulatory approval.
The company has said it will not seek to profit from the vaccine during the pandemic.
Researchers said the vaccine caused minor side effects more frequently than a control group.
But some of these could be reduced by taking paracetamol, with no serious adverse events from the vaccine.
Health Secretary Matt Hancock said the update on the vaccine was “very encouraging news”.
He tweeted: “We have already ordered 100 million doses of this vaccine, should it succeed.
“Congratulations to the scientists at UniofOxford & OxfordVacGroup and leadership of AstraZeneca.”
This is a breaking story…more to follow
Source: Read Full Article